Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

Novartis

Status: Completed

Conditions: Secondary Progressive Multiple Sclerosis (SPMS)

Treatments: Drug: Mayzent

Study type: Observational

Funder types: Industry

Identifiers

NCT04593927

CBAF312A1401

Details and patient eligibility

About

This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.

Full description

This is a non-interventional study, and as such there is no binding treatment strategy, diagnosis/treatment procedures or visit schedule. The investigator should administer Mayzent as labelled. Routine medical practice will apply to visit frequency and evaluation variables, and only these data will be collected by the sponsor as part of the study procedures. The investigator should record data in the applicable CRFs at every visit if possible.

Enrollment: 451 patients

Sex: All

Ages: Under 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients prescribed Mayzent for prevention of relapses and delay of progression of physical disability in secondary progressive multiple sclerosis

Exclusion criteria

Trial design

451 participants in 1 patient group

Mayzent

Description:

Patients administered Mayzent by prescription

Treatment:

Drug: Mayzent